Clovis Oncology (CLVS) Posts Wider Q2 Loss

Clovis Oncology (NASDAQ: CLVS) reported Q2 EPS of ($1.03), $0.07 worse than the analyst estimate of ($0.96).

“This is a very busy and exciting time at our Company,” said Patrick J. Mahaffy, President and CEO of Clovis Oncology. “We are rapidly enrolling patients in the rociletinib (CO-1686) Phase 2 expansion cohorts and TIGER2 studies, preparing for our NDA submission in mid-2015 and beginning to build out our commercial and medical affairs leadership in anticipation of a potential launch by year-end 2015. Additionally, the emerging results from the rucaparib ARIEL2 study are extremely encouraging and we look forward to presenting data for each of these programs at scientific meetings in the fall.”

For earnings history and earnings-related data on Clovis Oncology (CLVS) click here.

You May Also Be Interested In

• Okta upgraded as AI security opportunity boosts outlook
• On Holding AG (ONON) PT Lowered to $73 at UBS on Short-Term Industry Dynamics
• First Watch (FWRG) Reiterated at Buy by DA Davidson: Potential for Same-Store-Sales Upside